XENON PHARMACEUTICALS INC. (NASDAQ:XENE) Files An 8-K Other Events

Item 8.01

On June 27, 2017, Xenon Pharmaceuticals Inc. (the Company) and
its collaboration partner, Teva Pharmaceutical Industries, Ltd.
(Teva), issued a joint press release announcing results from the
Phase 2 clinical trial of topical TV-45070 in patients with
post-herpetic neuralgia. The clinical trial was conducted by
Teva. A copy of the press release is attached hereto as Exhibit
99.1 and is incorporated herein by reference, except for the
information set forth under the headings About Teva and Teva
Cautionary Note Regarding Forward-Looking Statements.

The Company will host a conference call and live audio webcast at
9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) on June 27, 2017
to discuss the topline results from the clinical trial. The live
call may be accessed by dialing (855) 779-9075 for domestic
callers or (631) 485-4866 for international callers, and
providing conference ID number 47072480. The webcast will be
broadcast live on the investors section of the Company’s
website.

(d) Exhibits.

Xenon Pharmaceuticals Inc. Exhibit
EX-99.1 2 xene-ex991_120.htm EX-99.1 xene-ex991_120.htm                        Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint   Jerusalem & Burnaby,…
To view the full exhibit click here
About XENON PHARMACEUTICALS INC. (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company’s platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies). Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes. Its integrated platform includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. Its pharmaceutical partners include Teva Pharmaceutical Industries, Ltd. (Teva), Genentech, Inc. (Genentech) and Merck & Co., Inc. (Merck). Extreme Genetics discovery platform has yielded the first approved gene therapy product in the European Union, or the EU, and a development pipeline, including Glybera, TV-45070, GDC-0276 and GDC-0310, and XEN801.